Personalized Cancer Vaccine Shows Promise in Melanoma Trial - Oncology News Central
Personalized Cancer Vaccine Shows Promise in Melanoma Trial Oncology News Central
The signal today is the first positive Phase 3 for a personalized neoantigen vaccine: Moderna and Merck's mRNA shot plus Keytruda met its primary endpoint in resected high-risk/advanced melanoma, moving the category from proof-of-concept toward regulatory filing and repricing both stocks sharply.CNBCOncology News Central
The rest of the tape is early-stage — NantBioScience's YENEO-001 draws analyst coverage in Phase I TNBC, and a pipeline profile highlights its yeast/peptide-based neoantigen approach.Pharmaceutical TechnologyPatsnap Synapse Net read: the field now spans a validated mRNA personalization platform at scale plus earlier, delivery-diverse entrants.
Personalized Cancer Vaccine Shows Promise in Melanoma Trial Oncology News Central
Relevant work from earlier we're still surfacing — not today's news.